Gino Santini

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA.

Greater Indianapolis Chamber of Commerce, Inc. operates as a chamber of commerce. It specializes in talent attraction, economic development, entrepreneur services, business advocacy, events, and membership. The company is headquartered in Indianapolis, IN.

United Way of Central Indiana, Inc. provides social services. The firm specializes in health, financial stability, community impact, live united, basic needs and connecting resources. The company was founded in 1986 and is headquartered in Indianapolis, IN.

The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC.

Indiana Chamber of Commerce operates as business advocacy organization. The firm provides economic opportunity and prosperity for the people of Indiana and their enterprises. It offers health care savings, employment posters and office solutions. The company was founded in 1922 and is headquartered in Indianapolis, IN.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Noble of Indiana operates as an organization for disabled care services. The non-profit company is based in Indianapolis, IN.

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Part of Societe Generale De Partecipations Agro-Alimentaires SA, Finanziaria Saccarifera Italo Iberica SpA operates as a real estate agency. The private company is based in Cesena, Italy.